First Trust NYSE Arca Biotech Index Fd

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Veracyte Receives Medicare Coverage for Bladder Cancer Test, Orders Open June 1

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Illumina CEO joins China delegation, stock price rises

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Leqembi® Iqlik™ PDUFA date updated to August 24th

FDA Prioritizes Review of LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's Disease

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Pinned News

置顶新闻

Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO

ETON

IBBQ

LABU

SBIO

ARKG

Eton Pharmaceuticals has secured exclusive U.S. rights to IMPAVIDO, the only FDA-approved oral therapy for leishmaniasis, set for launch on September 26, 2026. This agreement enhances Eton's rare-disease portfolio, which includes ten marketed products and four in late-stage development. CEO Sean Brynjelsen emphasized IMPAVIDO's critical role in their orphan-focused model. Eton's stock closed at $32.89, up 1.23%, and rose to $33.91 in after-hours trading.

nasdaq

Eton Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VanEck Biotech ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

SPDR S&P Biotech

Ark Genomic Revolution ETF

Nasdaq

The High Throughput Screening Market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a CAGR of 10.7%. Key drivers include increased drug discovery activities and rising R&D spending in pharmaceuticals and biotechnology. North America is expected to maintain the largest market share, supported by advanced laboratory infrastructure and strong R&D activity. Major companies in this sector include Thermo Fisher Scientific, Agilent Technologies, and Merck KGaA.

prnewswire

Thermo Fisher Scentific

Agilent Tech

10:15 ETHigh Throughput Screening Market worth $45.90 billion by 2031 | MarketsandMarkets™

LLYX

ELIL

The 2026 Milliman Medical Index reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase—the highest in over a decade. Key drivers include a 14.8% rise in pharmacy costs, influenced by GLP-1 drugs, and a 7.5% increase in outpatient facility costs. The report highlights the role of AI in optimizing billing processes, contributing to this significant cost growth.

- The Milliman Medical Index for 2026 reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase, the highest in over a decade.  
- Contributing factors include a 14.8% rise in pharmacy costs driven by GLP-1 drugs and high-cost specialty medications, alongside a 7.5% increase in outpatient facility costs.  
- Additionally, the introduction of artificial intelligence in billing processes is noted as a significant new factor in these rising costs.

MorningStar

Eli Lilly

Novo Nordisk AS

SPDR S&P Health

iShares Global Healthcare

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Long NVO ETF

SPDR Pharmac

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

ARWR

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is entering a pivotal phase with new regulatory approvals and early commercial progress for REDEMPLO. The company anticipates Phase 3 data from SHASTA-3 and SHASTA-4 studies in severe hypertriglyceridemia by Q3. Executives expressed optimism about the studies' potential to show statistical significance on acute pancreatitis. Additionally, SHASTA-5 aims to evaluate acute pancreatitis events in high-risk patients, with data expected by late 2027 or early 2028. Arrowhead projects REDEMPLO could achieve peak revenues of $3 billion to $4 billion.

Market Beat

ArrowHead Pharma

ROYAL BANK OF CANADA

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

PODD

Eli Lilly (LLY) has a forward P/E of 25.4, higher than the healthcare sector and S&P 500 averages, justified by strong growth projections. Insulet (PODD) also in healthcare, has a lower forward P/E but higher CAGR projections for revenue and EPS compared to Lilly.

Dow Jones

Insulet

iShares US Medical Devices

SPDR S&P Health Equip

S&P 500

These 15 S&P 500 stocks could be contrarian -2-

159859

Upsher-Smith, a subsidiary of Bora Pharmaceuticals, has launched a generic version of Restasis (cyclosporine ophthalmic emulsion) 0.05% in the US, following FDA clearance for its ANDA in January 2026. The US market for cyclosporine ophthalmic emulsion is valued at approximately $1.9 billion, according to IQVIA data.

PUBT

Proshares UltraShort Nasdaq Biotech

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

IQVIA

Upsher-Smith launches Restasis generic cyclosporine ophthalmic emulsion 0.05%

Engage Biologics Inc. has been acquired by Eli Lilly and Company for up to $202 million to enhance the development of non-viral genetic medicines. Engage's Tethosome platform aims to improve DNA delivery's potency, tolerability, and redosability. The acquisition combines Engage's innovative technology with Lilly's extensive genetic medicine capabilities, promising to accelerate the development of new genetic therapies.

Fidelity

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

Bristol Myers Squibb (BMY) is partnering with Anthropic to implement its Claude AI model for over 30,000 employees, aiming to enhance drug discovery and development processes. The initiative includes using Claude Code for various functions, moving beyond simple chatbot applications. BMY shares rose 1.74% to close at $58.31.

Tip Ranks

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

NVIDIA

Bristol-Myers Squibb Company

NVIDIA Corporation

BMY Stock Rises as Bristol Myers Brings Anthropic's Claude AI to 30,000 Employees

ROIV

MRNA

Roivant Sciences (NASDAQ:ROIV) reported strong Q4 2026 results, highlighting a $2.25 billion settlement with Moderna and advancements in its drug pipeline. The company has $4.3 billion in cash, no debt, and is actively repurchasing shares. Key developments include promising data from the 1402 study for rheumatoid arthritis and plans to launch Brepocitinib for dermatomyositis by September, pending FDA approval. Roivant remains optimistic about its pipeline and upcoming milestones in various therapeutic areas.

benzinga_article

Roivant Sciences

Moderna

Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript

RLAY

Citizens Jmp raised the price target for Relay Therapeutics (NASDAQ: RLAY) from $19.00 to $21.00, maintaining a 'market outperform' rating. This suggests a potential upside of 73.99% from the previous close. Other analysts have also set targets ranging from $21.00 to $26.00, with a consensus rating of 'Moderate Buy' and an average price target of $22.60.

Relay Therapeutics

UBS Group AG

Citigroup

Wells Fargo

Raymond James Financial

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Relay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Citizens Jmp

NBTX

Nanobiotix aims to revolutionize a long-standing cancer treatment method with innovative physics-based approaches. This leading biotech stock has seen significant growth, capturing the attention of Wall Street.

Unusual Whales

Nanobiotix SA

How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer

First Trust NYSE Arca Biotech Index Fd(FBT.US)